BioCryst clears HSR hurdle for Astria acquisition; expects close Q1 2026

BIOCRYST PHARMACEUTICALS INC

HSR waiting period terminated early on December 3, 2025, satisfying one closing condition.
BioCryst expects the merger with Astria Therapeutics to close in Q1 2026.
Remaining conditions still required; deal previously announced.
Removal of antitrust risk is a positive step toward closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.